Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MMP13 | P45452 | 2/20 | 0.63 |
| ▸ | PLK1 | P53350 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628526 | 0.85 | HPGD (0.79) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL15579337 | 0.85 | HDAC6 (0.50) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL13184545 | 0.84 | HPGD (1.00) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL3184688 | 0.81 | PPARA (0.53) | HPGDTSHRSMN1; SMN2MAPTRAB9A | |
| SCHEMBL6252549 | 0.81 | HPGD (0.85) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL5375128 | 0.81 | HPGD (0.85) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL30552374 | 0.81 | HPGD (0.43) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL21628855 | 0.80 | HPGD (0.76) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL21628640 | 0.79 | HPGD (0.69) | HPGDTSHRHTTSMN1; SMN2MMP13 | |
| SCHEMBL15577869 | 0.79 | HPGD (0.69) | HPGDTSHRHTTSMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HPGD 1041/4885TSHR 2412/4885HTT 1005/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HPGD 1041/4885TSHR 2412/4885HTT 1005/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | HPGD 1057/4885TSHR 2875/4885HTT 1617/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | HPGD 1298/4885TSHR 2547/4885HTT 1328/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HPGD 1041/4885TSHR 2412/4885HTT 1005/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HPGD 1041/4885TSHR 2412/4885HTT 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.